Related Experiment Videos
Proliferative potential of brain metastases
K G Cho1, T Hoshino, L H Pitts
1Brain Tumor Research Center, University of California School of Medicine, San Francisco.
Cancer
|August 1, 1988
Summary
Metastatic brain tumors show higher proliferation rates than their primary counterparts. Bromodeoxyuridine (BUdR) labeling index revealed increased S-phase cells in brain metastases, suggesting faster growth.
Area of Science:
- Oncology
- Cancer Biology
- Neuro-oncology
Background:
- Metastatic brain tumors represent a significant clinical challenge.
- Understanding the proliferative capacity of brain metastases is crucial for treatment strategies.
Purpose of the Study:
- To assess the proliferative potential of metastatic brain tumors.
- To compare the proliferation of brain metastases with their primary tumors.
Main Methods:
- Thirteen patients with brain metastases underwent intravenous infusion of bromodeoxyuridine (BUdR).
- Excised tumor tissue was analyzed using immunohistochemistry to determine the BUdR labeling index (LI).
- Tumor histology was classified, and LI was correlated with differentiation grade.
Main Results:
- All analyzed brain tumors exhibited a BUdR LI exceeding 5% (mean 13.3%).
- Moderately and poorly differentiated adenocarcinomas showed higher LI (median 15.3%) compared to well-differentiated adenocarcinomas (median 8.2%).
- Observed LI values were significantly higher than those typically reported for primary tumors.
Conclusions:
- Metastatic brain tumors demonstrate a higher proliferative rate than their primary origins.
- The increased proliferation suggests that brain metastases may grow more rapidly.
- These findings have implications for understanding tumor progression and developing targeted therapies.